biotechinvesting
Australia-based Cleo Diagnostics (ASX:COV) is poised to offer a groundbreaking solution for ovarian cancer screening through innovative blood tests that promise accurate and early cancer detection. In a recent interview, Cleo Diagnostics CEO Dr. Richard Allman discussed the company's path to revolutionise ovarian cancer screening. The insidious nature of ovarian cancer, which often goes undetected until it's too late, has necessitated a fresh approach to early diagnosis. Allman explained that the prototype test from Cleo Diagnostics exhibits a 95 percent sensitivity and specificity rate, and h...
Investing News Network
Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare. According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains. Data was collected on April 16, 2024, using TradingView's stock scr...
Investing News Network
The first quarter of 2024 brought a surge of initial public offerings (IPOs) and M&A activity within the biotech industry, signaling continued interest from investors who are keen to get exposure to the life science sector. Punctuating the period, AstraZeneca (LSE:AZN,NASDAQ:AZN) announced plans in March to acquire its longtime partner Fusion Pharmaceuticals, as well as startup Amolyt, which is focused on rare endocrine diseases. At the time of this writing, 14 biotech deals had been struck in 2024, according to data from Biopharma Dive. Meanwhile, data from investment bank Jefferies shows tha...
Investing News Network
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら